Cargando…

Outcomes of Anlotinib Maintenance Therapy in Patients With Advanced NSCLC in a Real-World Setting

BACKGROUND: Anlotinib is a novel tyrosine kinase inhibitor with promising anti-tumor activity in patients with advanced non-small cell lung cancer (NSCLC). The aim of this study was to evaluate the efficacy and safety of anlotinib maintenance therapy in patients with advanced NSCLC in real-world sit...

Descripción completa

Detalles Bibliográficos
Autores principales:	Li, Jia, Han, Baohui, Liu, Huaimin
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2022
Materias:	Oncology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9282872/ https://www.ncbi.nlm.nih.gov/pubmed/35847883 http://dx.doi.org/10.3389/fonc.2022.785865

Ejemplares similares

Pembrolizumab Plus Chemotherapy or Anlotinib vs. Pembrolizumab Alone in Patients With Previously Treated EGFR-Mutant NSCLC
por: Chen, Ya, et al.
Publicado: (2021)

Real-World Efficacy and Safety of Anlotinib With and Without Immunotherapy in Advanced Non-Small Cell Lung Cancer
por: Xiong, Qi, et al.
Publicado: (2021)

Integrated Transcriptome Analysis Reveals KLK5 and L1CAM Predict Response to Anlotinib in NSCLC at 3rd Line
por: Lu, Jun, et al.
Publicado: (2019)

A real-world study of anlotinib as third-line or above therapy in patients with her-2 negative metastatic breast cancer
por: Shao, Yingbo, et al.
Publicado: (2022)

The real-world efficacy and safety of anlotinib in advanced non-small cell lung cancer
por: Wang, Fen, et al.
Publicado: (2021)

Pembrolizumab-combination therapy for previously untreated metastatic nonsquamous NSCLC: Real-world outcomes at US oncology practices
por: Liu, Stephen V., et al.
Publicado: (2022)

Efficacy and Safety of Anlotinib in the Treatment of Small Cell Lung Cancer: A Real-World Observation Study
por: Yuan, Jing, et al.
Publicado: (2022)

Efficacy of immunotherapy in KRAS-mutant advanced NSCLC: A real-world study in a Chinese population
por: Peng, Lixiu, et al.
Publicado: (2023)

Predictive value of microvascular density for response to anlotinib in advanced NSCLC
por: Liu, Danqing, et al.
Publicado: (2022)

Long-term survival with anlotinib as a front-line treatment in an elderly NSCLC patient: A case report
por: Wang, Jingyi, et al.
Publicado: (2023)

Safety and Efficacy of Chemotherapy Combined with Anlotinib Plus Anlotinib Maintenance in Chinese Patients with Advanced/Metastatic Soft Tissue Sarcoma
por: Wang, Hai-ying, et al.
Publicado: (2020)

Retrospective Review of Efficacy and Safety of Anlotinib in Advanced Leiomyosarcoma: A Real-World Study
por: Zou, Hanhui, et al.
Publicado: (2022)

Diagnostic-Therapeutic Pathway and Outcomes of Early Stage NSCLC: a Focus on EGFR Testing in the Real-World
por: Pasello, Giulia, et al.
Publicado: (2022)

S-1 Maintenance Therapy After First-Line Treatment With Nab-Paclitaxel Plus S-1 for Advanced Pancreatic Adenocarcinoma: A Real-World Study
por: Shi, Yan, et al.
Publicado: (2022)

Real-world study of patients with locally advanced HNSCC in the community oncology setting
por: Black, Christopher M., et al.
Publicado: (2023)

Association between anlotinib trough plasma concentration and treatment outcomes in advanced non-small-cell lung cancer
por: Chen, Ling, et al.
Publicado: (2023)

A Real-World Study of Optimal Treatment with Anlotinib First-Line Therapy in Advanced Hepatocellular Carcinoma
por: Li, Qingqing, et al.
Publicado: (2022)

Anlotinib Downregulates RGC32 Which Provoked by Bevacizumab
por: Liu, Zhujun, et al.
Publicado: (2022)

Clinical Study of Anlotinib as Third-Line or Above Therapy in Patients With Advanced or Metastatic Gastric Cancer: A Multicenter Retrospective Study
por: Nie, Caiyun, et al.
Publicado: (2022)

Efficacy and safety of anlotinib plus programmed death-1 blockade versus anlotinib monotherapy as second or further-line treatment in advanced esophageal squamous cell carcinoma: A retrospective study
por: Liu, Ying, et al.
Publicado: (2022)

Prognostic factors of refractory NSCLC patients receiving anlotinib hydrochloride as the third- or further-line treatment
por: Wang, Jing, et al.
Publicado: (2018)

Pembrolizumab Alone or Combined With Chemotherapy in Advanced NSCLC With PD-L1 ≥50%: Results of a Retrospective Study
por: Chen, Ya, et al.
Publicado: (2021)

Levels of pretreatment blood lipids are prognostic factors in advanced NSCLC patients treated with anlotinib
por: Tang, Mengqiu, et al.
Publicado: (2021)

Longitudinal Pharmacometabonomics for Predicting Malignant Tumor Patient Responses to Anlotinib Therapy: Phenotype, Efficacy, and Toxicity
por: Hu, Ting, et al.
Publicado: (2020)

Gemcitabine Plus Anlotinib Is Effective and Safe Compared to Gemcitabine Plus Docetaxel in Advanced Soft Tissue Sarcoma
por: Liu, Zhiyong, et al.
Publicado: (2022)

The efficacy and safety of anlotinib combined with platinum-etoposide chemotherapy as first-line treatment for extensive-stage small cell lung cancer: A Chinese multicenter real-world study
por: Zheng, Hao-Ran, et al.
Publicado: (2022)

Is ICI-based therapy better than chemotherapy for metastatic NSCLC patients who develop EGFR-TKI resistance? A real-world investigation
por: Cheng, Yajie, et al.
Publicado: (2022)

Real-world data to build explainable trustworthy artificial intelligence models for prediction of immunotherapy efficacy in NSCLC patients
por: Prelaj, Arsela, et al.
Publicado: (2023)

Efficacy and Safety of Anlotinib in Patients with Advanced Non-Small Cell Lung Cancer: A Real-World Study
por: Zhong, Qiuxia, et al.
Publicado: (2021)

Efficacy and Safety of Anlotinib in Advanced Non-Small Cell Lung Cancer: A Real-World Study
por: Zhang, Kun, et al.
Publicado: (2020)

Editorial: Emerging Biomarkers for NSCLC: Recent Advances in Diagnosis and Therapy
por: Malapelle, Umberto, et al.
Publicado: (2021)

Novel Nutrition-Based Nomograms to Assess the Outcomes of Lung Cancer Patients Treated With Anlotinib or Apatinib
por: Zheng, Hui, et al.
Publicado: (2021)

A Retrospective Analysis of the Effect of Anlotinib in Patients With Lung Cancer With or Without Previous Antiangiogenic Therapy
por: Suo, Jiaojiao, et al.
Publicado: (2021)

Anlotinib Combined With Anti-PD-1 Antibodies Therapy in Patients With Advanced Refractory Solid Tumors: A Single-Center, Observational, Prospective Study
por: Yuan, Min, et al.
Publicado: (2021)

Efficacy of apatinib 250 mg combined with chemotherapy in patients with pretreated advanced breast cancer in a real-world setting
por: Zhang, Ruyan, et al.
Publicado: (2023)

Efficacy and Safety of Anlotinib in Overall and Disease-Specific Advanced Gynecological Cancer: A Real-World Study
por: Hong, Xinyi, et al.
Publicado: (2023)

Survival of NSCLC Patients Treated with Cimavax-EGF as Switch Maintenance in the Real-World Scenario
por: Flores Vega, Yoanna I., et al.
Publicado: (2023)

Case Report: Long-term remission of malignant pleural and peritoneal effusion in a case of advanced lung adenocarcinoma treated with combined crizotinib and anlotinib therapy
por: Tian, Jin, et al.
Publicado: (2023)

Real-world prospective analysis of treatment patterns in durvalumab maintenance after chemoradiotherapy in unresectable, locally advanced NSCLC patients
por: Taugner, Julian, et al.
Publicado: (2021)

Efficacy and Safety of Anlotinib Combined with Liposomal Doxorubicin Followed by Anlotinib Maintenance in Metastatic Soft Tissue Sarcomas
por: Liu, Zhiyong, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_u7squt88ru6teqjij8rh240hua